BACKGROUND AND OBJECTIVES: Pegylated interferon (peg-IFN)-α2a and -α2b show different pharmacokinetic properties but are used interchangeably for hepatitis C treatment in traditional dual combinations and with newer agents. We assessed whether peg-IFN antiviral effects vary with peg-IFN subtype, affecting viral response in a differential manner. METHODS: Chronic hepatitis C patients treated with ribavirin combined with peg-IFN-α2a (N = 109) or -α2b (N = 114) were studied. Hepatitis C virus RNA quantitation was performed by Cobas TaqMan 5 min before treatment start and subsequently after 48/72 h and 7, 14, 28 and 90 days. Antiviral effect was assessed in terms of viraemia changes over treatment. Histology grading and staging, interleukin-28B (IL28B) status and baseline viral genotype, alanine aminotransferase, gamma glutamyltransferase and glucose were analysed. RESULTS: Viraemia decline after 48/72 h and 7 days was significantly greater with peg-IFN-α2b (1.96 and 2.12 vs 1.49 and 1.20 log10 IU/mL with peg-IFN-α2a; p < 0.001). Differences were of larger extent in patients with advanced fibrosis (p = 0.002), genotype 1 infection (p = 0.002) and CT/TT genotypes of IL28B (p = 0.001). A rebound in viral load was observed significantly more often after the first dose in patients treated with peg-IFN-α2b (78 vs 28 % in those with peg-IFN-α2a; p = 0.0001). Differences between peg-IFNs disappeared by day 28 of treatment. CONCLUSION: There are significant pharmacodynamic differences between peg-IFN-α2a and -α2b in the early phase of chronic hepatitis C treatment. The greater early viral decline observed with peg-IFN-α2b was essentially confined to 'difficult to treat' patients. Whether this could affect response-guided treatment decision making, as well as triple drug regimens, needs to be assessed.
BACKGROUND AND OBJECTIVES: Pegylated interferon (peg-IFN)-α2a and -α2b show different pharmacokinetic properties but are used interchangeably for hepatitis C treatment in traditional dual combinations and with newer agents. We assessed whether peg-IFN antiviral effects vary with peg-IFN subtype, affecting viral response in a differential manner. METHODS:Chronic hepatitis Cpatients treated with ribavirin combined with peg-IFN-α2a (N = 109) or -α2b (N = 114) were studied. Hepatitis C virus RNA quantitation was performed by Cobas TaqMan 5 min before treatment start and subsequently after 48/72 h and 7, 14, 28 and 90 days. Antiviral effect was assessed in terms of viraemia changes over treatment. Histology grading and staging, interleukin-28B (IL28B) status and baseline viral genotype, alanine aminotransferase, gamma glutamyltransferase and glucose were analysed. RESULTS:Viraemia decline after 48/72 h and 7 days was significantly greater with peg-IFN-α2b (1.96 and 2.12 vs 1.49 and 1.20 log10 IU/mL with peg-IFN-α2a; p < 0.001). Differences were of larger extent in patients with advanced fibrosis (p = 0.002), genotype 1 infection (p = 0.002) and CT/TT genotypes of IL28B (p = 0.001). A rebound in viral load was observed significantly more often after the first dose in patients treated with peg-IFN-α2b (78 vs 28 % in those with peg-IFN-α2a; p = 0.0001). Differences between peg-IFNs disappeared by day 28 of treatment. CONCLUSION: There are significant pharmacodynamic differences between peg-IFN-α2a and -α2b in the early phase of chronic hepatitis C treatment. The greater early viral decline observed with peg-IFN-α2b was essentially confined to 'difficult to treat' patients. Whether this could affect response-guided treatment decision making, as well as triple drug regimens, needs to be assessed.
Authors: S Zeuzem; E Herrmann; J H Lee; J Fricke; A U Neumann; M Modi; G Colucci; W K Roth Journal: Gastroenterology Date: 2001-05 Impact factor: 22.682
Authors: Marcelo Silva; Jorge Poo; Frank Wagner; Mary Jackson; David Cutler; Michael Grace; Ronald Bordens; Connie Cullen; Joann Harvey; Mark Laughlin Journal: J Hepatol Date: 2006-04-18 Impact factor: 25.083
Authors: T Witthoeft; D Hueppe; C John; J Goelz; R Heyne; B Moeller; G Teuber; S Wollschlaeger; A Baumgarten; K-G Simon; G Moog; N Dikopoulos; S Mauss Journal: J Viral Hepat Date: 2010-02-11 Impact factor: 3.728
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: Emanuele Durante-Mangoni; Rosa Zampino; Giuseppe Portella; Luigi E Adinolfi; Riccardo Utili; Giuseppe Ruggiero Journal: Clin Infect Dis Date: 2009-08-15 Impact factor: 9.079
Authors: Jennifer E Layden; Thomas J Layden; K Rajender Reddy; Rachel S Levy-Drummer; Jennifer Poulakos; Avidan U Neumann Journal: J Viral Hepat Date: 2002-09 Impact factor: 3.728
Authors: Maria Grazia Rumi; Alessio Aghemo; Gian Maria Prati; Roberta D'Ambrosio; Maria Francesca Donato; Roberta Soffredini; Ersilio Del Ninno; Antonio Russo; Massimo Colombo Journal: Gastroenterology Date: 2009-09-18 Impact factor: 22.682